Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29516254 | 1.00 | ALDH1A1 (0.61) | ALDH1A1CES2CES1L3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL16594352 | 0.98 | ALDH1A1 (0.59) | ALDH1A1CES2CES1L3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL31098456 | 0.98 | ALDH1A1 (0.59) | ALDH1A1CES2CES1L3MBTL1LMNA | |
| Furan SCHEMBL3664221 | 0.89 | ALDH1A1 (0.50) | ALDH1A1CES2CES1L3MBTL1LMNA | |
| Trifluoroacetic Acid SCHEMBL31197677 | 0.88 | LMNA (0.50) | ALDH1A1CES2CES1L3MBTL1LMNA | |
| SCHEMBL11254855 | 0.86 | ALDH1A1 (0.59) | ALDH1A1CES2CES1L3MBTL1LMNA | |
| SCHEMBL18428315 | 0.84 | ALDH1A1 (0.57) | ALDH1A1CES2CES1L3MBTL1LMNA | |
| SCHEMBL20709045 | 0.84 | ALDH1A1 (0.57) | ALDH1A1CES2CES1L3MBTL1LMNA | |
| SCHEMBL28129295 | 0.84 | ALDH1A1 (0.57) | ALDH1A1CES2CES1L3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL22583360 | 0.82 | ALDH1A1 (0.55) | ALDH1A1CES2CES1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069605-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | claimed |
| US-12486260-B2 | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | MERCK PATENT GMBH (DE) | 2025-12-02 | — | — | US | claimed |
| WO-2025080593-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR AND PD-1 INHIBITOR OR PD-L1 INHIBITOR | INCYTE CORPORATION (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025080592-A1 | COMBINATION COMPRISING A KRAS G12D INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2025-04-17 | — | — | WO | claimed |
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | claimed |
| US-20240368156-A1 | 2-AZABICYCLO[2.2.1]HEPTANE KRAS INHIBITORS | INCYTE CORPORATION | 2024-11-07 | — | — | US | claimed |
| EP-4415824-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-08-21 | — | — | EP | claimed |
| US-20240208969-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2024-06-27 | — | — | US | claimed |
| EP-4326713-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2024-02-28 | — | — | EP | claimed |
| WO-2023064857-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-04-20 | — | — | WO | claimed |
| EP-0915874-B1 | PROCESS OF PREPARATION OF VALACYCLOVIR AND RELEVANT INTERMEDIATES | IND CHIMICA SRL (IT) | 2003-12-10 | — | — | EP | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| EP-0915874-A2 | PROCESS OF PREPARATION OF VALACYCLOVIR AND RELEVANT INTERMEDIATES | INDUSTRIALE CHIMICA S.r.l. (IT) | 1999-05-19 | — | — | EP | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998003553-A1 | PROCESS OF PREPARATION OF VALACYCLOVIR AND RELEVANT INTERMEDIATES | INDUSTRIALE CHIMICA S.R.L. (IT) | 1998-01-29 | — | — | WO | claimed |
| EP-0377357-B1 | Process for the condensation of at least one epoxide on at least one cyclic anhyhride in the presence of a titanium-based catalyst | INST FRANCAIS DU PETROLE (FR) | 1994-03-23 | — | — | EP | claimed |
| EP-0204535-B1 | N-FLUOROPYRIDINIUM SALT AND PROCESS FOR PREPARING SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-08-19 | — | — | EP | claimed |
| US-4997910-A | Polyesters | INSTITUT FRANCAIS DU PETROLE (FR) | 1991-03-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | HIPK1, NEK1, HIPK2 | ALDH1A1 2398/4885CES2 3925/4885CES1 1733/4885 |
| US-20240208969-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | PARP1, PARP3, PARP11 | ALDH1A1 217/4885CES2 2142/4885CES1 1528/4885 |
| US-20240368156-A1 | 2-AZABICYCLO[2.2.1]HEPTANE KRAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 1476/4885CES2 4746/4885CES1 3416/4885 |
| US-12486260-B2 | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | KIT, TNNI3K, CILK1 | ALDH1A1 421/4885CES2 2997/4885CES1 1740/4885 |
| US-20260069605-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 966/4885CES2 4391/4885CES1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.